Table 1.
Quality Measures for Patients with PTSD and Patients with Depression
| Measure No. | PTSD | Depression |
|---|---|---|
| Assessment | ||
| A1 | Percentage of PTSD patients with a new treatment episode with assessment of symptoms with PCL within 30 days | Percentage of depression patients with a new treatment episode with assessment of symptoms with PHQ-9 within 30 days |
| A2 | Percentage of PTSD patients with a new treatment episode assessed for depression within 30 days | Percentage of depression patients with a new treatment episode assessed for manic/hypomanic behaviors within 30 days |
| A3 | Percentage of PTSD patients with a new treatment episode assessed for suicide risk at same visit | Percentage of depression patients with a new treatment episode assessed for suicide risk at same visit* |
| A4 | Percentage of PTSD patients with a new treatment episode assessed for recent substance use within 30 days | Percentage of depression patients with a new treatment episode assessed for recent substance use within 30 days |
| Treatment | ||
| T1 | Percentage of PTSD patients with symptom assessment with PCL during 4-month measurement period | Percentage of depression patients with symptom assessment with PHQ-9 during 4-month measurement period* |
| T3 | Percentage of patient contacts of PTSD patients with SI with appropriate follow-up (PTSD-T3) | Percentage of patient contacts of depression patients with SI with appropriate follow-up (Depression-T3) |
| T5 | Percentage of PTSD patients with a newly prescribed SSRI/SNRI with an adequate trial (≥ 60 days) | Percentage of depression patients with a newly prescribed antidepressant with a trial of 12 weeks (T5a) or 6 months (T5b)* |
| T6 | Percentage of PTSD patients newly prescribed an SSRI/SNRI with follow-up visit within 30 days | Percentage of depression patients newly prescribed an antidepressant with follow-up visit within 30 days |
| T7 | Percentage of PTSD patients who receive evidence-based psychotherapy for PTSD | Percentage of depression patients who receive evidence-based psychotherapy for depression |
| T8 | Percentage of PTSD patients with a new treatment episode who received any psychotherapy within the first 4 months | Percentage of depression patients with a new treatment episode who received any psychotherapy within the first 4 months |
| T9 | Percentage of PTSD patients with a new treatment episode with 4 psychotherapy visits or 2 evaluation and management visits in the first 8 weeks | Percentage of depression patients with a new treatment episode with 4 psychotherapy visits or 2 evaluation and management visits in the first 8 weeks |
| T10 | Percentage of PTSD patients (PCL score > 43) with response to treatment (5-point reduction in PCL score) at 6 months | Percentage of depression patients (PHQ-9 score > 9) with response to treatment (50% reduction in PHQ-9 score) at 6 months* |
| T12 | Percentage of PTSD patients (PCL score > 43) in PTSD-symptom remission (PCL score < 28) at 6 months | Percentage of depression patients (PHQ-9 score > 9) in depression-symptom remission (PHQ-9 score < 5) at 6 months* |
| T14 | Percentage of PTSD patients with a new treatment episode with improvement in functional status at 6 months | Percentage of depression patients with a new treatment episode with improvement in functional status at 6 months |
| T15 | Percentage of psychiatric inpatient hospital discharges of patients with PTSD with follow-up in 7 days (T15a) or 30 days (T15b)* | Percentage of psychiatric inpatient hospital discharges of patients with depression with follow-up in 7 days (T15a) or 30 days (T15b)* |
NOTE: PCL = PTSD Checklist; PHQ-9 = Patient Health Questionnaire, 9-item; SSRI = selective serotonin reuptake inhibitor; SNRI = serotonin and norepinephrine reuptake inhibitor.
*
National Quality Forum (NQF)-endorsed measure.